Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.71 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284563 | 1.00 | AR (1.00) | ARNR3C1BACE1ACHEMAOB | |
| SCHEMBL12271712 | 0.93 | AR (0.87) | ARNR3C1BACE1GAASIGMAR1 | |
| SCHEMBL3910141 | 0.84 | AR (0.72) | ARNR3C1BACE1 | |
| SCHEMBL20874524 | 0.84 | NR3C1 (0.75) | ARNR3C1BACE1SIGMAR1ESR2 | |
| SCHEMBL20874523 | 0.84 | NR3C1 (0.75) | ARNR3C1BACE1SIGMAR1ESR2 | |
| SCHEMBL3284537 | 0.83 | AR (1.00) | ARNR3C1ESR2 | |
| SCHEMBL12272157 | 0.83 | NR3C1 (0.74) | ARNR3C1ESR2 | |
| SCHEMBL3292306 | 0.83 | NR3C1 (0.74) | ARNR3C1ESR2 | |
| SCHEMBL5424997 | 0.83 | NR3C1 (0.74) | ARNR3C1ESR2 | |
| SCHEMBL3291858 | 0.83 | AR (1.00) | ARNR3C1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713989-B2 | Glucocorticoid receptor modulators | DOW ROBERT L | 2010-05-11 | — | — | US | disclosed |
| US-20070117805-A1 | Glucocorticoid receptor modulators | PFIZER INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117805-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | AR 84/4885NR3C1 1/4885BACE1 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.